Novel Hepatitis E Vaccine Protects for at Least a Decade
A three-dose vaccine regimen prevented hepatitis E virus (HEV) infections with high efficacy in adults over the course of 10 years, a phase III trial from China found. The HEV239 vaccine, sold under the name Hecolin outside the U.S., had an efficacy rate of 83.1% (95% CI 69.4-91.4) in the study’s modified intention-to-treat analysis and […]
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A
Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of immunosuppressive therapy in this vulnerable population, a phase II study showed. Over 12 weeks of therapy, a high-dose regimen of the factor VIIIa mimetic antibody yielded a low mean breakthrough bleeding rate […]
Bempedoic Acid Gets ‘Huge’ Win for Primary Prevention in the Statin-Intolerant
SAN DIEGO — Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial confirmed. In these patients, bempedoic acid was associated with a large decrease in risk of major adverse cardiovascular events (MACE) compared with placebo over a median 39.9 […]
Monoclonal antibody may prevent malaria
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial […]